0001567619-22-002521.txt : 20220204 0001567619-22-002521.hdr.sgml : 20220204 20220204164939 ACCESSION NUMBER: 0001567619-22-002521 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220202 FILED AS OF DATE: 20220204 DATE AS OF CHANGE: 20220204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCarthy Sean A. CENTRAL INDEX KEY: 0001654058 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 22594120 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD. STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2022-02-02 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001654058 McCarthy Sean A. C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2022-02-02 4 A 0 75000 0.00 A 174922 D Common Stock 93158 I See footnote Stock Option (Right to Buy) 4.13 2022-02-02 4 A 0 450000 0.00 A 2032-02-01 Common Stock 450000 450000 D Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 75,000 RSUs. Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. /s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy 2022-02-04